Outlook Therapeutics to Present at EURETINA Innovation Spotlight

Outlook Therapeutics will present at the 2025 EURETINA Innovation Spotlight on September 3, 2025, in Paris. Bob Jahr, CEO, will present "Optimising the treatment of retinal disease" in the VEGF Related and Other Retinal Indications session. Outlook Therapeutics focuses on optimizing bevacizumab treatment for retina diseases and has received marketing authorization for LYTENAVA (bevacizumab gamma) in Europe for wet AMD.

Outlook Therapeutics (NASDAQ: OTLK), a biopharmaceutical company specializing in bevacizumab treatments for retina diseases, will present at the 2025 EURETINA Innovation Spotlight. The presentation, titled "Optimising the treatment of retinal disease," will be delivered by CEO Bob Jahr on September 3, 2025, at 16:10 PM CEST / 10:10 AM EDT in Paris, France.

The presentation will focus on the company's efforts to optimize the standard of care for bevacizumab in the treatment of retina diseases. Outlook Therapeutics has received marketing authorization for LYTENAVA™ (bevacizumab gamma) in Europe for the treatment of wet AMD. The company's ONS-5010/LYTENAVA™ (bevacizumab-vikg) is currently under investigation in the United States. Despite the FDA's Complete Response Letter (CRL) for ONS-5010/LYTENAVA™ due to a lack of substantial evidence of effectiveness, the company is committed to addressing the regulatory concerns and advancing its therapeutic potential.

References:

[1] https://www.stocktitan.net/news/OTLK/outlook-therapeutics-to-present-at-the-2025-euretina-innovation-keyraxjtd89i.html
[2] https://www.stocktitan.net/news/OTLK/outlook-therapeutics-provides-regulatory-update-on-u-s-food-and-drug-nbyjrm2bh7f4.html